Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial
Bibliographic record
Abstract
AbS has received support from the FRSQ-Junior 1 clinician scientist award, the Alberta Innovates Health Solution Clinician Scientist fellowship, the European Society of Cardiology Young Investigator research grant, Janssen, Roche Diagnostics, AstraZeneca, Boehringer Ingelheim, Novartis, Servier, Novo Nordisk and the Canadian Cardiovascular Society Bayer Vascular award. PM has no disclosures. ApS is an employee of New Arch Consulting and received funding from Janssen for this analysis. FGA and WR are employees of Janssen. BLN received fees for travel support, advisory boards, scientific presentations and steering committee roles from AstraZeneca, Bayer, Boehringer Ingelheim, Cambridge Healthcare Research and Janssen, with all honoraria paid to his institution. RAF is supported by a PhD studentship from the Health Data Research UK-The Alan Turing Institute Wellcome Trust Programme in Health Data Science. This funding had no role in the production of this article. CA received honoraria from Amgen; received support from a National Health and Medical Research Council/Medical Research Future Fund, Priority Fellowship and an NSW Health EMC grant; and is an employee of the George Institute for Global Health. AL served as a scientific advisor to Boehringer Ingelheim, AstraZeneca, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), OccuRx and Chinook Therapeutics; served on a data safety monitoring board or scientific committee for NIDDK, NIH, Kidney Precision Medicine, CURE consortium and the University of Washington Kidney Research Institute Scientific Advisory Committee; received research funding from Canadian Institutes of Health Research, Kidney Foundation of Canada, GSK, AstraZeneca and Boehringer Ingelheim; and received fees for time as CREDENCE national coordinator from Janssen, directed to her academic team. SV holds a Tier 1 Canada Research Chair in Cardiovascular Surgery. SV has also received grants and personal fees for speaker honoraria and advisory board participation from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Amgen, HLS, Merck, EOCI Pharmacomm Ltd, Novartis, Sun Pharmaceuticals and Toronto Knowledge Translation Working Group. He also serves as President of the Canadian Medical and Surgical Knowledge Translation Research Group. VP received fees for an advisory board, steering committee, or scientific presentation from AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Chinook Therapeutics, CSL Vifor, Gilead, GSK, Janssen, MedImmune, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Otsuka and Travere Therapeutics, Inc.; received speaker fees from Janssen; served on a data and safety monitoring committee for Dimerix; served on the board of directors for George Clinical, Garvan Institute, George Institute, Victor Chang Cardiac Research Institute, Ingham Institute and Mindgardens Neuroscience Network; and has stock in George Clinical. KWM has received research support from Afferent, Amgen, Apple, Inc., AstraZeneca, Cardiva Medical, Inc., Daiichi, Ferring, Google (Verily), Johnson &Johnson, Luitpold, Medtronic, Merck, National Institutes of Health, Novartis, Sanofi, St Jude, and Tenax. Kenneth Mahaffey also has served as a consultant (speaker fees for continuing medical education events only) for Abbott, Ablynx, AstraZeneca, Baim Institute, Boehringer Ingelheim, Bristol-Myers Squibb, Elsevier, GlaxoSmithKline, John-son & Johnson, MedErgy, Medscape, Mitsubishi, Myokardia, National Institutes of Health, Novartis, Novo Nordisk, Portola, Radiometer, Regeneron, Springer Publishing and University of California, San Francisco. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15340. The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.006 | 0.022 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.002 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.002 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.003 |
| Insufficient payload (model declined to judge) | 0.005 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".